Trastuzumab FDA approval date

The FDA approved Trastuzumab (Herceptin) on 25 Sep 1998.

FDA approval date
25 Sep 1998

Drug identity checked against registry records

Also recorded as Herceptin; Herceptin®

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127ALX Oncology Inc.Phase 2, Phase 3Completed2024-05-24Actual
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsNCT01953926PBYIPhase 2Terminated2023-01-02Actual
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711MacroGenicsPhase 3Completed2021-08-11Actual
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559ALX Oncology Inc.Phase 2Recruiting2027-12Estimated
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCNCT04262804Zai Lab (Shanghai) Co., Ltd.Phase 2Unknown2021-09-03Actual
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364MacroGenicsPhase 2, Phase 3Completed2024-01-15Actual
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Jazz PharmaceuticalsPhase 2Recruiting2027-12-29Estimated
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147Jazz PharmaceuticalsPhase 3Active not recruiting2026-07-15Actual
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429Jazz PharmaceuticalsPhase 3Recruiting2028-04-28Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
1998-09-25DayTrastuzumabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA103792", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["HERCEPTIN"], "active_ingredients": ["TRASTUZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19980925", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026